78 related articles for article (PubMed ID: 10718088)
21. Ribavirin approved with a big fat price.
Falkenberg J
Notes Undergr; 1998; (No 37):10-1. PubMed ID: 11365818
[TBL] [Abstract][Full Text] [Related]
22. Decisions, decisions, decisions.
Koretz RL
Gastroenterology; 2000 Jun; 118(6):1268-70. PubMed ID: 10833503
[No Abstract] [Full Text] [Related]
23. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.
San Miguel R; Mar J; Cabasés JM; Guillén-Grima F; Buti M
Aliment Pharmacol Ther; 2003 Mar; 17(6):765-73. PubMed ID: 12641498
[TBL] [Abstract][Full Text] [Related]
24. [Hepatitis C in Egypt, a iatrogenic epidemic].
Vrolijk JM; Schalm SW
Ned Tijdschr Geneeskd; 2000 Dec; 144(49):2378. PubMed ID: 11129975
[No Abstract] [Full Text] [Related]
25. Combination therapy for hepatitis C infection.
Newman TB
N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
[No Abstract] [Full Text] [Related]
26. Does the "C" in hepatitis C stand for complex?
Huber D
Gastroenterol Nurs; 2001; 24(3):120-6; quiz 127-8. PubMed ID: 11847861
[TBL] [Abstract][Full Text] [Related]
27. Interferon plus ribavirin for chronic hepatitis C.
Med Lett Drugs Ther; 1999 Jun; 41(1054):53-4. PubMed ID: 10368698
[No Abstract] [Full Text] [Related]
28. Letter to the editor.
Druyts E; Thorlund K; Mills EJ
J Med Econ; 2014 Jul; 17(7):445. PubMed ID: 24702240
[No Abstract] [Full Text] [Related]
29. A pharmacoeconomic appraisal of therapies for hepatitis B and C.
Younossi ZM; Temple ME; Shermock KM
Expert Opin Pharmacother; 2001 Feb; 2(2):205-11. PubMed ID: 11336580
[TBL] [Abstract][Full Text] [Related]
30. Outcomes research in chronic viral hepatitis C: effects of interferon therapy.
Bonkovsky HL; Woolley JM
Can J Gastroenterol; 2000; 14 Suppl B():21B-29B. PubMed ID: 10938501
[TBL] [Abstract][Full Text] [Related]
31. Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
Congly SE; Lee SS
Aliment Pharmacol Ther; 2014 Oct; 40(8):983-4. PubMed ID: 25229813
[No Abstract] [Full Text] [Related]
32. How cost-effective is hepatitis C virus treatment for people who inject drugs?
Martin NK; Vickerman P; Miners A; Hickman M
J Gastroenterol Hepatol; 2013 Apr; 28(4):590-2. PubMed ID: 23527756
[No Abstract] [Full Text] [Related]
33. Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.
Saab S; Younossi ZM
Aliment Pharmacol Ther; 2014 Oct; 40(8):984-5. PubMed ID: 25229814
[No Abstract] [Full Text] [Related]
34. Interferon-alpha for chronic hepatitis C: reducing the uncertainties.
Koff RS
Ann Intern Med; 1997 Nov; 127(10):918-20. PubMed ID: 9382371
[No Abstract] [Full Text] [Related]
35. Depression Disorders in Patients with Chronic Hepatitis C.
Bebek-Ivankovic H; Bevanda M; Susak B; Grgic S; Soldo-Coric L; Nikolic J
Psychiatr Danub; 2020 Nov; 32(Suppl 4):540-546. PubMed ID: 33212461
[TBL] [Abstract][Full Text] [Related]
36. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.
Rentiya ZS; Wells M; Bae J; Chen KJ; Chao AN; Turgeon N; Shah SM; Hanout M
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):447-452. PubMed ID: 30547319
[TBL] [Abstract][Full Text] [Related]
37. [Not Available].
Wolf E; Rüsenberg R
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():42-5. PubMed ID: 26048120
[No Abstract] [Full Text] [Related]
38. Tolerability of treatments for viral hepatitis.
Gervais A; Boyer N; Marcellin P
Drug Saf; 2001; 24(5):375-84. PubMed ID: 11419564
[TBL] [Abstract][Full Text] [Related]
39. The science, economics, and effectiveness of combination therapy for hepatitis C.
Dusheiko G; Barnes E; Webster G; Whalley S
Gut; 2000 Aug; 47(2):159-61. PubMed ID: 10896900
[No Abstract] [Full Text] [Related]
40. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
Koff RS
J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
